Screening and Prevention of Hereditary Gynecologic Cancers

Seminars in Oncology

Volumn 34, Issue 5, 2007, Pages 406-410

  Kehoe, Siobhan M ^a   Kauff, Noah D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ARTICLE; BRCA2 GENE; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CHEMOPROPHYLAXIS; COLONOSCOPY; COLORECTAL CANCER; ENDOMETRIUM CANCER; FAMILIAL CANCER; FAMILY HISTORY; GENE; GENE MUTATION; GENETIC ANALYSIS; GYNECOLOGIC CANCER; HEREDITARY BREAST OVARIAN CANCER SYNDROME; HEREDITARY NONPOLYPOSIS COLON CANCER SYNDROME; HUMAN; MISMATCH REPAIR; MMR GENE; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SALPINGOOOPHORECTOMY;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENITAL NEOPLASMS, FEMALE; HUMANS; MUTATION; OVARIAN NEOPLASMS;

EID: 34848847148     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2007.07.004     Document Type: Article

References (49)

1. Rubin SC, Blackwood MA, Bandera C, et al: BRCA1, BRCA2 and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol 178:670-677, 998
2. Risch H.A., McLaughlin J.R., Cole D.E., et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68 (2001) 700-710
3. Pal T., Permuth-Wey J., Betts J.A., et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104 (2005) 2807-2816
4. Struewing J.P., Hartge P., Wacholder S., et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336 (1997) 1401-1408
5. Ford D., Easton D.F., Stratton M., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62 (1998) 676-689
6. Antoniou A., Pharoah P.D., Narod S., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72 (2003) 1117-1130
7. King M.C., Marks J.H., Mandell J.B., and New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 (2003) 643-646
8. Boyd J., Sonoda Y., Federici M.G., et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283 (2000) 2260-2265
9. Ries LAG, Harkins D, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2003/, accessed August 4, 2006
10. Scheuer L., Kauff N., Robson M., et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20 (2002) 1260-1268
11. Liede A., Karlan B.Y., Baldwin R.L., et al. Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol 20 (2002) 1570-1577
12. Hogg R., and Friedlander M. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 22 (2004) 1315-1327
13. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology-V.1.2006. Genetic/Familial High Risk Assessment: Breast and Ovarian Cancer. http://www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf
14. Grimes D.A., and Economy K.E. Primary prevention of gynecologic cancers. Am J Obstet Gynecol 172 (1995) 227-235
15. Whittemore A.S., Belise R.R., Pharoah P.D., et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer 91 (2004) 1911-1915
16. Narod S.A., Risch H., Moslehi R., et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 339 (1998) 424-428
17. Modan B., Hartge P., Hirsh-Yechezkel G., et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345 (2001) 235-240
18. Narod S.A., Dube M.P., Klijn J., et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94 (2002) 1773-1779
19. Liber A.M. Ovarian cancer in a mother and five daughters. Arch Pathol 49 (1950) 280-290
20. Tobacman J.K., Greene M.H., Tucker M.A., et al. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 2 (1982) 795-797
21. Piver M.S., Jishi M.F., Tsukada Y., et al. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 71 (1993) 2751-2755
22. Struewing J.P., Watson P., Easton D.F., et al. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr 17 (1995) 33-35
23. Kauff N.D., Satagopan J.M., Robson M.E., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346 (2002) 1609-1615
24. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346 (2002) 1616-1622
25. Rutter J.L., Wacholder S., Chetrit A., et al. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: An Israeli population-based case-control study. J Natl Cancer Inst 95 (2003) 1072-1078
26. Eisen A., Lubinski J., Klijn J., et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: An international case-control study. J Clin Oncol 23 (2005) 7491-7496
27. Domchek S.M., Friebel T.M., Neuhausen S.L., et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: A prospective cohort study. Lancet Oncol 7 (2006) 223-229
28. Finch A., Beiner M., Lubinski J., et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 296 (2006) 185-192
29. Society of Gynecologic Oncologists. Clinical Practice Committee Statement on Prophylactic Salpingo-Oophorectomy. Gynecol Oncol 98 (2005) 179-181
30. Satagopan J.M., Boyd J., Kauff N.D., et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 8 (2002) 3776-3781
31. Kauff N.D., Mitra M., Robson M.E., et al. Risk of ovarian cancer in BRCA1 and BRCA2 mutation negative hereditary breast cancer families. J Natl Cancer Inst 97 (2005) 1382-1384
32. Muller A., and Fishel R. Mismatch repair and the hereditary nonpolyposis colorectal cancer (HNPCC). Cancer Invest 20 (2002) 102-109
33. Hampel H., Frankel W., Panescu J., et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 66 (2006) 7810-7817
34. Vasen H.F., Winjen J.T., Menko F.H., et al. Cancer risk in patients with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110 (1996) 1020-1027
35. Aarnio M., Sankila R., Pakkula E., et al. Cancer risk in mutation carriers of DNA-mismatch repair genes. Int J Cancer 81 (1999) 214-218
36. Dunlop M.G., Farrington S.M., Carothers A.D., et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6 (1997) 105-110
37. Lu K.H., Dinh M., Kohlmann W., et al. Gynecologic cancer as a "sentinel cancer" for women with the hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 105 (2005) 569-574
38. Vasen H.F., Mecklin J.P., Khan P.M., et al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 34 (1991) 424-425
39. Vasen H.F., Watson P., Mecklin J.P., et al. New clinical criteria hereditary nonpolyposis colorectal cancer. (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116 (1999) 1453-1456
40. Rodriguez-Bigas M.A., Boland C.R., Hamilton S.R., et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: Meeting highlights and Bethesda guidelines. J Natl Cancer Inst 89 (1997) 1758-1762
41. Umar A., Boland C.R., Terdiman J.P., et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96 (2004) 261-268
42. Guillem J.G., Wood W.C., Moley J.F., et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 24 (2006) 4642-4660
43. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology-V.1.2007. Colorectal Cancer Screening. http://www.nccn.org/professionals/physician_gls/PDF/colorectal_screening.pdf
44. Lindor N.M., Peterson G.M., Hadley D.W., et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: A systemic review. JAMA 296 (2006) 1507-1517
45. Jarvinen H.J., Aarnio M., Mustonen H., et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118 (2000) 829-834
46. Dove-Edwin I., Boks D., Goff S., et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 94 (2002) 1708-1712
47. Rijcken F., Mourits M., Kleibeuker J., et al. Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 91 (2003) 74-80
48. Schmeler K.M., Lynch H.T., Chen L., et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354 (2006) 261-269
49. Offit K., and Kauff N.D. Reducing the risk of gynecologic cancer in the Lynch syndrome. N Engl J Med 354 (2006) 293-295